CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.)

306 articles with CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.)

• CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting

  10/2/2020

  CASI Pharmaceuticals, Inc. announced that research conducted at the New York Blood Center investigating the impact of CID-103 on RBC pretransfusion test methods, will be presented at the American Association of Blood Banks Virtual Annual Meeting being held October 3-5, 2020.

• CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd

  9/29/2020

  CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced a restructuring of its partnership with Juventas Cell Therapy Ltd. relating to CNCT19, an investigational CD19 CAR-T Cell therapy.

• CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September 2020 Conferences

  9/11/2020

  CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the following upcoming virtual conferences in September.

• CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results

  8/10/2020

  - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results and business highlights for the

• CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020

  8/3/2020

  CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced the Company will host a conference call reviewing the second quarter highlights at 4:30 p.m. ET on Monday, August 10th, 2020.

• CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock

  7/22/2020

   CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $1.90 per share.

• CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock

  7/21/2020

   CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

• CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program

  6/8/2020

  CASI Pharmaceuticals, Inc. announced that it submitted a Clinical Trial Application with the United Kingdom's Medicines and Healthcare Products Regulatory Agency for CID-103, its novel anti-CD38 monoclonal antibody for the treatment of multiple myeloma and other hematological malignancies.

• CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference

  6/2/2020

  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He , Chairman & CEO will present an overview of the company and provide a business update at the Jefferies 2020 He

• CASI Pharmaceuticals Announces First Quarter 2020 Financial Results

  5/11/2020

  - Company to host Conference Call Today at 4:30 p.m. ET -

• CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference

  4/7/2020

  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He , Chairman & CEO will present an overview of the company and provide a business update at the Solebury Trout V

• CASI Pharmaceuticals Announces Full Year 2019 Financial Results

  3/16/2020

   CASI Pharmaceuticals today reported financial results for the year ended December 31, 2019.

• CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications

  12/4/2019

  CASI Pharmaceuticals, Inc. announces that the China National Medical Product Administration, has approved the clinical trial applications for CNCT19 in relapsed/refractory B-cell acute lymphoblastic leukemia and relapsed/refractory B-cell non-Hodgkin lymphoma submitted by its partner Juventas Cell Therapy Ltd., a biopharmaceutical company focused on cell therapy.

• CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results

  11/12/2019

  CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, reported financial results for the third quarter and nine months ended September 30, 2019.

• CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly

  11/7/2019

  CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces an exclusive distribution agreement with Pharmathen Global BV for the development and distribution of octreotide long acting injectable microsphere in China.

• 

  BioSpace Movers & Shakers, Sept. 20

  9/20/2019

  Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.

• CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President

  9/19/2019

  He was instrumental with the successful launch of EVOMELA® and we expect Larry to continue to have an immediate impact on the growth and commercialization of our current and future pipeline

• China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product

  9/16/2019

  CASI Pharmaceuticals, Inc. announces that the Chinese National Medical Product Administration, the Chinese FDA, has accepted the clinical trial application for CNCT19 for investigation in relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

• CASI Pharmaceuticals, Inc. to Host Key Opinion Leader Symposium on September 10, 2019 in New York City

  9/5/2019

  CASI Pharmaceuticals, Inc. announces it will host a key opinion leader symposium addressing innovations in cancer immunotherapy and recent regulatory reforms impacting the China biopharmaceutical market.

• CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference

  9/3/2019

  CASI Pharmaceuticals, Inc. announces it will present at the 2019 H.C. Wainwright 21st Annual Global Investment Conference being held September 8-10, 2019 in New York, NY.